Search research articles
Contact Us
Filters
Showing results (261-270 of 304) with videos related to
Page
of 31
Sort By:
Nature Genetics
|
October 1, 1992
A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome
R Wooster, J Mangion, R Eeles, et al.
Cancer Research
|
August 1, 1992
Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment
A Butta, K MacLennan, K C Flanders, et al.
Annals of the New York Academy of Sciences
|
April 30, 1996
Oncogene products and other diagnostic markers in human breast cancer patients. Treatment effects and their significance
M Dowsett, A Makris, P Ellis, et al.
Lancet (London, England)
|
January 11, 2005
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
A Howell, J Cuzick, M Baum, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1991
Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer
B P Haynes, M Jarman, M Dowsett, et al.
Virchows Archiv : an International Journal of Pathology
|
January 1, 1995
Determining factors which predict response to primary medical therapy in breast cancer using a single fine needle aspirate with immunocytochemical staining and flow cytometry
I N Fernando, T J Powles, M Dowsett, et al.
Breast Cancer Research and Treatment
|
December 1, 1993
Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer
S R Johnston, B P Haynes, N P Sacks, et al.
Cancer Research
|
March 1, 1995
Idoxifene: report of a phase I study in patients with metastatic breast cancer
R C Coombes, B P Haynes, M Dowsett, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
July 17, 2012
Are Estring® and Vagifem® equally effective and safe for the treatment of urogenital atrophy in breast cancer patients on aromatase inhibitor therapy?
C E Simmons, I Kuchuk, O C Freedman, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|
February 3, 1999
The primary use of endocrine therapies
A Howell, E Anderson, R Blamey, et al.
Page
of 31
Search research articles
Search
Showing results (261-270 of 304) with videos related to
Sort By:
Page
of 31
Nature Genetics
|
October 1, 1992
A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome
R Wooster, J Mangion, R Eeles, et al.
Cancer Research
|
August 1, 1992
Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment
A Butta, K MacLennan, K C Flanders, et al.
Annals of the New York Academy of Sciences
|
April 30, 1996
Oncogene products and other diagnostic markers in human breast cancer patients. Treatment effects and their significance
M Dowsett, A Makris, P Ellis, et al.
Lancet (London, England)
|
January 11, 2005
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
A Howell, J Cuzick, M Baum, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1991
Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer
B P Haynes, M Jarman, M Dowsett, et al.
Virchows Archiv : an International Journal of Pathology
|
January 1, 1995
Determining factors which predict response to primary medical therapy in breast cancer using a single fine needle aspirate with immunocytochemical staining and flow cytometry
I N Fernando, T J Powles, M Dowsett, et al.
Breast Cancer Research and Treatment
|
December 1, 1993
Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer
S R Johnston, B P Haynes, N P Sacks, et al.
Cancer Research
|
March 1, 1995
Idoxifene: report of a phase I study in patients with metastatic breast cancer
R C Coombes, B P Haynes, M Dowsett, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
July 17, 2012
Are Estring® and Vagifem® equally effective and safe for the treatment of urogenital atrophy in breast cancer patients on aromatase inhibitor therapy?
C E Simmons, I Kuchuk, O C Freedman, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|
February 3, 1999
The primary use of endocrine therapies
A Howell, E Anderson, R Blamey, et al.
Page
of 31